Back to Cancer Australia's website

Cancer Australia

Select a guideline

Recommendations for use of Taxane-containing chemotherapy regimens

Unanswered questions

Important unanswered questions about the use of taxanes in early breast cancer are outlined below; some of these should be addressed in ongoing trials and with longer follow-up of reported trials:

  • optimal sequence/timing/duration of adjuvant taxanes with chemotherapy
  • optimal use/sequence/timing/duration of neoadjuvant taxanes with chemotherapy
  • the relative benefits and harms of different taxanes
  • potential long term/late toxicity associated with taxanes
  • use of taxanes in patients with node-negative tumours
  • use of taxanes in patients with >4 involved axillary lymph nodes
  • efficacy of taxanes with regards to hormone receptor status
  • efficacy of taxanes with regards to HER2 receptor status
  • relative benefits and harms of neoadjuvant use of taxanes compared to adjuvant use
  • the short and long-term effects of taxanes on quality of life.

Published using CeCC Docbook Manager